On Apr. 22, 2020, Cocrystal Pharma announced it has expanded its previously announced license agreement with Kansas State University Research Foundation (‘KSURF’) to include rights to additional preclinical leads and further develop certain proprietary broad-spectrum antiviral compounds for the treatment of COVID-19.

Cocrystal was granted an exclusive, royalty-bearing right and license to certain small molecule therapeutic inhibitors against coronaviruses, picornaviruses and caliciviruses covered by patent rights controlled by KSURF.